Studies are underway to evaluate the safety and efficacy of novel therapies for LS-SCLC, including ICIs that inhibit programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) (24, 25). This evidence concerns the gene CD274 and small cell lung carcinoma.